3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Terminated
1
Recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
2
Conditions
Breast Neoplasms
91
Neoplasm Metastasis
24
Neoplasms
14
Brain Neoplasms
13
Prostatic Neoplasms
10
Endometrial Neoplasms
10
Carcinoma, Non-Small-Cell Lung
10
Ovarian Neoplasms
7
Glioblastoma
7
Glioma
6
Triple Negative Breast Neoplasms
5
Squamous Cell Carcinoma of Head and Neck
5
Head and Neck Neoplasms
5
Colorectal Neoplasms
5
Sarcoma
4
Recurrence
4
Pancreatic Neoplasms
4
Lymphoma, Non-Hodgkin
4
Sarcoma, Ewing
3
Osteosarcoma
3
Neoplasms by Site
3
Multiple Myeloma
3
Meningioma
3
Melanoma
3
Carcinoma, Renal Cell
3
Breast Diseases
3
Unilateral Breast Neoplasms
2
Rhabdomyosarcoma
2
Rhabdoid Tumor
2
Oligodendroglioma
2
Interventions
Fulvestrant
18
Letrozole
8
Anastrozole
6
Capecitabine
5
palbociclib
4
olaparib
4
Paclitaxel
4
Goserelin
4
Docetaxel
4
pyrotinib
3
exemestane
3
Injections
3
toripalimab
2
sacituzumab govitecan
2
ribociclib
2
eribulin
2
elacestrant
2
abemaciclib
2
Vinorelbine
2
Trastuzumab
2
FCN-437c
2
Everolimus
2
Dasatinib
2
Aromatase Inhibitors
2
Alpelisib
2
Albumin-Bound Paclitaxel
2
AZD9833
2
vandetanib
1
trastuzumab deruxtecan
1
talazoparib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Interventional
×
Advanced Breast Cancer
×
abemaciclib
×
Clear all
NCT06380751
2026-05-15
EvoPAR-BR01
AstraZeneca
Phase 3
Recruiting
500 enrolled
NCT04227327
2025-07-29
HERMIONE-7
University of Milano Bicocca
Phase 2
Terminated
31 enrolled